Piekarczyk Andrzej, Kaminska Ewa, Taljanski Witold, Sosonowska Krystyna, Poszwinska Beata, Rutkowska Magdalena
Zaklad Farmakologii, Instytut Matki i Dziecka, Kasprzaka 17a, 01-211 Warszawa, Poland.
Med Wieku Rozwoj. 2003 Oct-Dec;7(4 Pt 2):547-55.
Our goal was to perform a pharmacokinetic analysis of netilmicin to develop the optimum dosage regimen of this antibiotic in premature neonates hospitalized in Neonate Intensive Care Unit of the Institute of Mother and Child in Warsaw.
The pharmacokinetics of netilmicin was studied in 80 neonates, divided for analysis into three groups according to gestational age: group I - 10 full-term neonates (b.w. 3225 +/-502 g); group II - 35 premature neonates between 29-32 weeks (b.w. 1134+/-311 g); and group III - 35 premature neonates between 23-28 weeks (b.w. 910 +/-243 g). The whole studied group of neonates was initially given i.v. netilmicin every 24 h, then the dosing interval for the safety reasons was prolonged to 48 h in the premature group. The neonates received netilmicin in the following doses: group I - mean dose 6.2 +/-0.42 mg/kg; group II - 5.911+/-0.529 mg/kg and group III - 6.014+/-0.313 mg/kg. Serum netilmicin concentrations were determined by fluorescence polarization immunoassay (FPIA) - TD(x)FL(x) (Abbott).
The mean of pharmacokinetic parameters for groups I, II, and III were defined respectively: t(0.5) (h): 7.14+/-1.88, 12.68+/-4.26, 15.98+/-5.9; AUC0-( (microg x h/ml): 149+/-41, 303+/-100, 401+/-172; Cl/kg (l/h/kg): 0.748+/-0.24, 0.371+/-0.13, 0.289+/-0.1; MRT0-( (h): 6.3+/-2.8, 10.8+/-6.3, 15.5+/-9.3; V(dss) (l/kg): 0.75+/-0.24, 0.59+/-0.52, 0.44+/-0.19. The obtained mean netilmicin serum concentrations (microg/ml) were: once-a-day dosage: C(max) - 10.25+/-2.616 (group I), 12.2+/-2.65 (group II), 12.9+/-2.77 (group III); C(min) - 1.158+/-0.657 (group I), - 2.65+/-1.02 (group II), 3.23+/-1.42 (group III); once-a-48 h dosage: C(max) - 11.7+/-1.09 (group II), 13.9+/-6.53 (group III); C(min) - 1.09+/-0.64 (group II), 1.74+/-0.98 (group III).
我们的目标是对奈替米星进行药代动力学分析,以制定这种抗生素在华沙母婴研究所新生儿重症监护病房住院的早产儿中的最佳给药方案。
对80例新生儿的奈替米星药代动力学进行了研究,根据胎龄将其分为三组进行分析:第一组 - 10例足月儿(体重3225±502克);第二组 - 35例29 - 32周的早产儿(体重1134±311克);第三组 - 35例23 - 28周的早产儿(体重910±243克)。整个研究组的新生儿最初每24小时静脉注射一次奈替米星,然后出于安全原因,早产儿组的给药间隔延长至48小时。新生儿接受的奈替米星剂量如下:第一组 - 平均剂量6.2±0.42毫克/千克;第二组 - 5.911±0.529毫克/千克,第三组 - 6.014±0.313毫克/千克。血清奈替米星浓度通过荧光偏振免疫分析法(FPIA) - TD(x)FL(x)(雅培)测定。
第一组、第二组和第三组药代动力学参数的平均值分别确定为:t(0.5)(小时):7.14±1.88,12.68±4.26,15.98±5.9;AUC0 - (微克·小时/毫升):149±41,303±100,401±172;Cl/kg(升/小时/千克):0.748±0.24,0.371±0.13,0.289±0.1;MRT0 - (小时):6.3±2.8,10.8±6.3,15.5±9.3;V(dss)(升/千克):0.75±0.24,0.59±0.52,0.44±0.19。获得的平均奈替米星血清浓度(微克/毫升)为:每日一次给药:C(max) - 10.25±2.616(第一组),12.2±2.65(第二组),12.9±2.77(第三组);C(min) - 1.158±0.657(第一组), - 2.65±1.02(第二组),3.23±1.42(第三组);每48小时一次给药:C(max) - 11.7±1.09(第二组),13.9±6.53(第三组);C(min) - 1.09±0.64(第二组),1.74±0.98(第三组)。